EIKCS 2022: Care for the whole patient
At the 2022 European International Kidney Cancer Symposium (EIKCS) in [...]
ESMO 2021: Pembrolizumab as adjuvant therapy
Adjuvant therapy is medication that is given in addition to [...]
Health-related quality of life for kidney cancer patients on pembrolizumab/lenvatinib
In this video, Dr Bradley McGregor from the Dana-Farber Cancer [...]
ASCO 2021: Health-related quality of life for lenvatinib plus pembrolizumab for advanced kidney cancer
Results from the phase 3 CLEAR study were presented at [...]
Quality versus quantity of life with cabozantinib and sunitinib in advanced kidney cancer
Cabozantinib and sunitinib are both drugs that block the development [...]
ESMO Virtual 2020: Quality of life impact of immune checkpoint inhibitors
Immune checkpoint inhibitors have changed the way renal cell carcinoma [...]
Survivorship and immune checkpoint inhibitors
In a study reported in the August issue of the [...]
Quality of life worse for cancer patients during COVID-19 pandemic
A paper published in Psycho-Oncology earlier this month suggests that patients [...]
Atezolizumab alone or in combination with bevacizumab for untreated metastatic kidney cancer
This paper reports patient-reported outcomes from the phase 2 IMmotion150 [...]
Integrative oncology: using evidence-based medicine to improve patient outcomes and quality of life
A recent article published in Cancer Therapy Advisor describes what [...]
